IncellDx, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
IncellDx, Inc. - overview
Location
Menlo Park, CA, US
Primary Industry
Healthcare
About
IncellDx, Inc. is a biotechnology firm specializing in single-cell diagnostics, focusing on advancing Precision Medicine through innovative tools for the analysis of proteomic and genomic biomarkers. IncellDx, Inc. is a biotechnology company that focuses on developing advanced diagnostic tools.
The company was co-founded by Bruce Patterson and Carol Penfold-Patterson and is headquartered in Menlo Park, California, US. In April 2012, the company raised USD 6 mn in venture financing from Bio-Reference Laboratories, Inc. , which was its most recent funding round. The company has completed a total of 2 deals.
IncellDx, Inc. specializes in single-cell diagnostics with a focus on advancing Precision Medicine. The company’s primary offerings include innovative diagnostic and prognostic tools that enable simultaneous analysis of proteomic and genomic biomarkers at the single-cell level. Notable products include the HPV OncoTect 3Dx CE-IVD Kit, tailored for specific international markets, along with a suite of assays and reagents designed for research use.
The company primarily serves healthcare providers, research institutions, and laboratories across multiple international markets compliant with local regulations. IncellDx operates through a business model focused on direct transactions with healthcare providers and research institutions, distributing its diagnostic products. Sales are structured around specific offerings such as the HPV E6, E7 mRNA Probe and Anti PD-L1 Antibody, sold in fixed quantities. Revenue is generated through one-time sales or bulk orders based on client requirements, with a pricing structure aligned with market standards for diagnostic tools.
Partnerships with distributors enhance the company's market reach and operational capacity, contributing to a robust revenue stream. IncellDx, Inc. aims to leverage the recent USD 6 mn funding raised in April 2012 to support the development of new diagnostic products and expand its presence in international markets. The company is focused on launching new innovations in single-cell diagnostics by the end of 2023, targeting expansion into Europe and other regions where its products can meet regulatory compliance.
This strategy is designed to enhance the company's reach in Precision Medicine and capitalize on emerging market opportunities.
Current Investors
Bio-Reference Laboratories, Inc.
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories
Website
www.incelldx.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
IncellDx, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.